[
  {
    "ts": null,
    "headline": "AbbVie Stock Rises After Leerink Partners Upgrades Its Rating",
    "summary": "Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.",
    "url": "https://finnhub.io/api/news?id=65ca21afd797240f947e2a0cb18f813360149febcbdc3a2c884e9a5483a1d1fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732564800,
      "headline": "AbbVie Stock Rises After Leerink Partners Upgrades Its Rating",
      "id": 131637891,
      "image": "https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.",
      "url": "https://finnhub.io/api/news?id=65ca21afd797240f947e2a0cb18f813360149febcbdc3a2c884e9a5483a1d1fb"
    }
  },
  {
    "ts": null,
    "headline": "Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead",
    "summary": "AbbVieâs promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.",
    "url": "https://finnhub.io/api/news?id=a7c2474282fff681842a27a6f7ad2957312ae7f8a364bcab7af19a104cb757e1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732559230,
      "headline": "Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead",
      "id": 131627040,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVieâs promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.",
      "url": "https://finnhub.io/api/news?id=a7c2474282fff681842a27a6f7ad2957312ae7f8a364bcab7af19a104cb757e1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock rises Monday, still underperforms market",
    "summary": "AbbVie Inc. stock rises Monday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=24de73b50524de1fa753662f642423ee9bf32b72a07df54161fbe2a0efca416b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732552500,
      "headline": "AbbVie Inc. stock rises Monday, still underperforms market",
      "id": 131636748,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock rises Monday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=24de73b50524de1fa753662f642423ee9bf32b72a07df54161fbe2a0efca416b"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Holiday-Shortened Week Starts Positively",
    "summary": "Wall Street's major market indices kicked off the holiday-shortened trading week on a positive note.",
    "url": "https://finnhub.io/api/news?id=dab12908255a18c41441195dfd8bab689a3117a81591178b31201f42de4b7c50",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732552200,
      "headline": "Wall Street Lunch: Holiday-Shortened Week Starts Positively",
      "id": 131626559,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345928727/image_1345928727.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Wall Street's major market indices kicked off the holiday-shortened trading week on a positive note.",
      "url": "https://finnhub.io/api/news?id=dab12908255a18c41441195dfd8bab689a3117a81591178b31201f42de4b7c50"
    }
  },
  {
    "ts": null,
    "headline": "High Growth Tech Stocks To Explore In November 2024",
    "summary": "The United States market has experienced a robust performance with a 2.2% climb over the past week and an impressive 32% increase over the last 12 months, while earnings are forecast to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.",
    "url": "https://finnhub.io/api/news?id=d2c34bc2f014c9646f900b7d89369ce59e0f3181f4f36865d703c68f3090f6de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732543793,
      "headline": "High Growth Tech Stocks To Explore In November 2024",
      "id": 131627492,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/41bdd0c670f621394929d5266c5d6c72",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The United States market has experienced a robust performance with a 2.2% climb over the past week and an impressive 32% increase over the last 12 months, while earnings are forecast to grow by 15% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.",
      "url": "https://finnhub.io/api/news?id=d2c34bc2f014c9646f900b7d89369ce59e0f3181f4f36865d703c68f3090f6de"
    }
  },
  {
    "ts": null,
    "headline": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
    "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
    "url": "https://finnhub.io/api/news?id=7b835e11e3dd59cbaccc5fe94a089290e93502e964fb7592f02d8ec37e7b5446",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732543680,
      "headline": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
      "id": 131630849,
      "image": "https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
      "url": "https://finnhub.io/api/news?id=7b835e11e3dd59cbaccc5fe94a089290e93502e964fb7592f02d8ec37e7b5446"
    }
  },
  {
    "ts": null,
    "headline": "Finding Winners In Biotech, Probably The Riskiest Sector",
    "summary": "Jonathan Faison shares his approach to investing in biotech, the 'riskiest' sector. Recent lows and seeing through the volatility.",
    "url": "https://finnhub.io/api/news?id=7c4d77f24653ebbe6e97ec170651bdb1659f6bcbb787689530bddbca7cce4392",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732541400,
      "headline": "Finding Winners In Biotech, Probably The Riskiest Sector",
      "id": 131625800,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Jonathan Faison shares his approach to investing in biotech, the 'riskiest' sector. Recent lows and seeing through the volatility.",
      "url": "https://finnhub.io/api/news?id=7c4d77f24653ebbe6e97ec170651bdb1659f6bcbb787689530bddbca7cce4392"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Present at Citi's 2024 Global Healthcare Conference",
    "summary": "AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024. Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., executive vice president, Research & Development and chief scientific officer, will present at 9:15 a.m. Central time.",
    "url": "https://finnhub.io/api/news?id=e5983729e0f0f8acd14df430e85606dd823dc56147374ccbe3bcd09ffad51094",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732539600,
      "headline": "AbbVie to Present at Citi's 2024 Global Healthcare Conference",
      "id": 131637897,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024. Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., executive vice president, Research & Development and chief scientific officer, will present at 9:15 a.m. Central time.",
      "url": "https://finnhub.io/api/news?id=e5983729e0f0f8acd14df430e85606dd823dc56147374ccbe3bcd09ffad51094"
    }
  }
]